AHR and neoplasm: This enzymatic activity establishes an immunosuppressive tumor microenvironment via two distinct pathways: GCN2-mediated T cell anergy resulting from tryptophan depletion, and AhR-dependent immune tolerance induced by accumulating kynurenine metabolites.